Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Hyperthermia. 2002 Nov-Dec;18(6):506-20.

Cancer immunotherapy: stress proteins and hyperthermia.

Author information

1
Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. masoud.manjili@roswellpark.org

Abstract

Heat shock proteins (hsps) can induce anti-cancer immune responses by targeting associated tumour antigens to the immune system. Hsps are not merely carriers of antigen but can also induce maturation of dendritic cells (DCs), resulting in a more efficient antigen presentation. However, improvement of hsp-based vaccines is still desirable if one is to realize their full therapeutic potential. Since the immune system consists of different elements functioning together in a highly integrated way, a combination therapy utilizing important immunomodulators together with hsp-based vaccination may improve therapeutic response. Hyperthermia has been shown to have important stimulatory effects on several cellular and organismal endpoints related to the immune system. This review highlights advantages and disadvantages of various ways of using stress proteins in cancer immunotherapy. It also overviews the interaction of hyperthermia with heat shock protein therapy and the related effects on the host's immune response.

PMID:
12537751
DOI:
10.1080/02656730110116696
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center